PDS Biotechnology is an immunotherapy company developing molecularly targeted immunotherapies designed to overcome the limitations of existing immunotherapy and vaccine technologies. Co.'s T cell activating platforms designed to train the immune system to attack and destroy disease; Versamune®, and Versamune plus PDS0301 for treatments in oncology; and Infectimune, for treatments in infectious disease. Co. develops targeted product candidates to treat several cancers including Human Papillomavirus-associated cancers, melanoma, colorectal, lung, breast and prostate cancers. Co.'s infectious disease candidates are of potential interest for use in COVID-19 and universal influenza vaccines. The PDSB average annual return since 2015 is shown above.
The Average Annual Return on the PDSB average annual return since 2015 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether PDSB average annual return since 2015 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the PDSB average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|